Medical artificial intelligence (AI) corporations Lunit said on Feb. 5 that it was selected as the supplier after participating in a public tender for breast cancer screening in Malta. It will introduce AI solutions to Malta's national breast cancer screening program for seven years.
Lunit supports mammography screening in Malta. Malta is a member of the European Union (EU). While there have been cases of AI adoption by private medical institutions in Europe, this is the first time AI has been introduced into a nationwide national screening program.
Lunit has supplied AI solutions to private medical institutions in Malta since 2023. This time, it has expanded supply to the public institutional sector. A Lunit official said, "Through validation by the Maltese government and medical officials, we verified safety and effectiveness."
Lunit has participated in regional breast cancer screening programs in the United Kingdom, Germany, France and Italy. Seo Beom-seok, Lunit's chief executive, said, "AI has gone beyond a simple clinical tool to become an important element in public health care infrastructure," adding, "We will become a model case for building an AI screening system."